{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:55:02Z","timestamp":1789664102131,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir Vet J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune-mediated haemolytic anaemia (IMHA) has a high mortality rate within the first weeks to months of diagnosis. Identifying dogs at increased risk of death may help guide decision-making for owners and veterinarians. Prior studies have identified several but inconsistent prognostic factors. The objectives of the study were to describe the clinical presentation and outcome of canine immune-mediated haemolytic anaemia in Ireland and to assess for independent factors associated with survival including long-term survival. Medical records from a single centre were reviewed between 2002 and 2020 to identify dogs with immune-mediated haemolytic anaemia using the American College of Veterinary Internal Medicine (ACVIM) consensus statement algorithm. Survival analysis was performed using univariable Cox proportional hazards regression models with Breslow method for ties to identify prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred and four cases were included. The diagnosis of immune-mediated haemolytic anaemia was classified as definitive, supportive and suspicious in 42 (40%), 50 (48%), and 12 dogs (12%) respectively. Twenty-two dogs (21%) were diagnosed with associative IMHA and 82 dogs were diagnosed with non-associative IMHA (79%). 65% of the cases received more than one immunosuppressive medication during the course of treatment. The mortality rate at one and three months was 16% (95% confidence interval [CI] 9\u201326) and 31% (95% CI 21\u201343) respectively. Excluding dogs that died within three months, the median survival time was 2664 days. The relapse rate during the follow-up period was 7%. Survival did not improve over the course of the study period. Thrombocytopenia and hyperbilirubinaemia were identified as negative prognostic indicators (Hazard ratio 2.2 and 2.5, 95% CI 1.1\u20134.1 and 1.1\u20135.6, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Excluding dogs that died within three months, the outcome was good in dogs with non-associative immune-mediated haemolytic anaemia in Ireland. The relapse rate was low regardless of the presence of associative causes. Thrombocytopenia and hyperbilirubinaemia were the only independent negative prognostic factors. The one-month and three-month mortality rates were similar compared to prior studies and survival did not improve over time during the study period: the mortality rate of canine immune-mediated haemolytic anaemia remains high in the acute phase.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13620-024-00277-w","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T09:02:43Z","timestamp":1721898163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical presentation, outcome and prognostic factors in dogs with immune-mediated haemolytic anaemia: a retrospective single-centre study of 104 cases in Ireland (2002\u20132020)"],"prefix":"10.1186","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8957-6108","authenticated-orcid":false,"given":"Antoine A.","family":"Duclos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther L\u00f3pez","family":"Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Le Boedec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Cuq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"3","key":"277_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/01652176.2011.604979","volume":"31","author":"CJ Piek","year":"2011","unstructured":"Piek CJ. Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research. Vet Q. 2011;31(3):129\u201341.","journal-title":"Vet Q"},{"issue":"4","key":"277_CR2","first-page":"217","volume":"29","author":"A Balch","year":"2007","unstructured":"Balch A, Mackin A. Canine immune-mediated hemolytic anemia: pathophysiology, clinical signs, and diagnosis. Compend Contin Educ Vet. 2007;29(4):217\u201325.","journal-title":"Compend Contin Educ Vet"},{"issue":"6","key":"277_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cvsm.2020.07.010","volume":"50","author":"R Goggs","year":"2020","unstructured":"Goggs R. Therapeutic strategies for treatment of Immune-mediated hemolytic Anemia. Vet Clin North Am Small Anim Pract. 2020;50(6):1327\u201349.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"3","key":"277_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/jvim.15463","volume":"33","author":"JW Swann","year":"2019","unstructured":"Swann JW, Garden OA, Fellman CL, Glanemann B, Goggs R, LeVine DN, et al. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med. 2019;33(3):1141\u201372.","journal-title":"J Vet Intern Med"},{"issue":"1\u20132","key":"277_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1751-0813.2009.00537.x","volume":"88","author":"TJ McAlees","year":"2010","unstructured":"McAlees TJ. Immune-mediated haemolytic anaemia in 110 dogs in Victoria, Australia. Aust Vet J. 2010;88(1\u20132):25\u20138.","journal-title":"Aust Vet J"},{"key":"277_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1746-6148-7-15","volume":"7","author":"CJ Piek","year":"2011","unstructured":"Piek CJ, van Spil WE, Junius G, Dekker A. Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anemia: a retrospective cohort study. BMC Vet Res. 2011;7:15.","journal-title":"BMC Vet Res"},{"issue":"6","key":"277_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/jvim.13642","volume":"29","author":"R Goggs","year":"2015","unstructured":"Goggs R, Dennis SG, Di Bella A, Humm KR, McLauchlan G, Mooney C, et al. Predicting Outcome in dogs with primary Immune-mediated hemolytic Anemia: results of a Multicenter Case Registry. J Vet Intern Med. 2015;29(6):1603\u201310.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"277_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/avj.12302","volume":"93","author":"SS Ke","year":"2015","unstructured":"Ke SS, Anderson GA, Connolly SL. Evaluation of prognostic indicators for canine primary immune-mediated haemolytic anaemia and application of a scoring system for the determination of prognosis. Aust Vet J. 2015;93(4):93\u20138.","journal-title":"Aust Vet J"},{"issue":"5","key":"277_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5326\/15473317-35-5-384","volume":"35","author":"ME Reimer","year":"1999","unstructured":"Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988\u20131996). J Am Anim Hosp Assoc. 1999;35(5):384\u201391.","journal-title":"J Am Anim Hosp Assoc"},{"issue":"12","key":"277_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/avj.12875","volume":"97","author":"C Weingart","year":"2019","unstructured":"Weingart C, Thielemann D, Kohn B. Primary immune-mediated haemolytic anaemia: a retrospective long-term study in 61 dogs. Aust Vet J. 2019;97(12):483\u20139.","journal-title":"Aust Vet J"},{"issue":"4","key":"277_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1292\/jvms.09-0283","volume":"72","author":"M Ishihara","year":"2010","unstructured":"Ishihara M, Fujino Y, Setoguchi A, Takahashi M, Nakashima K, Ohno K, et al. Evaluation of prognostic factors and establishment of a prognostic scoring system for canine primary immune-mediated hemolytic anemia. J Vet Med Sci. 2010;72(4):465\u201370.","journal-title":"J Vet Med Sci"},{"issue":"5","key":"277_CR12","first-page":"504","volume":"16","author":"AP Carr","year":"2002","unstructured":"Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med. 2002;16(5):504\u20139.","journal-title":"J Vet Intern Med"},{"issue":"7","key":"277_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1748-5827.2011.01074.x","volume":"52","author":"JW Swann","year":"2011","unstructured":"Swann JW, Skelly BJ. Evaluation of immunosuppressive regimens for immune-mediated haemolytic anaemia: a retrospective study of 42 dogs. J Small Anim Pract. 2011;52(7):353\u20138.","journal-title":"J Small Anim Pract"},{"issue":"2","key":"277_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1939-1676.2008.0060.x","volume":"22","author":"CJ Piek","year":"2008","unstructured":"Piek CJ, Junius G, Dekker A, Schrauwen E, Slappendel RJ, Teske E. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med. 2008;22(2):366\u201373.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"277_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jvim.12514","volume":"29","author":"JW Swann","year":"2015","unstructured":"Swann JW, Skelly BJ. Systematic review of prognostic factors for mortality in dogs with immune-mediated hemolytic anemia. J Vet Intern Med. 2015;29(1):7\u201313.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"277_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1476-4431.2010.00551.x","volume":"20","author":"ML Holahan","year":"2010","unstructured":"Holahan ML, Brown AJ, Drobatz KJ. The association of blood lactate concentration with outcome in dogs with idiopathic immune-mediated hemolytic anemia: 173 cases (2003\u20132006). J Vet Emerg Crit Care (San Antonio). 2010;20(4):413\u201320.","journal-title":"J Vet Emerg Crit Care (San Antonio)"},{"issue":"4","key":"277_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2460\/javma.2001.218.543","volume":"218","author":"SA Grundy","year":"2001","unstructured":"Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989\u20131999). J Am Vet Med Assoc. 2001;218(4):543\u20136.","journal-title":"J Am Vet Med Assoc"},{"issue":"11","key":"277_CR18","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2460\/javma.252.11.1384","volume":"252","author":"A Zoia","year":"2018","unstructured":"Zoia A, Gerou-Ferriani M, Drigo M, Caldin M. Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc. 2018;252(11):1384\u201392.","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"277_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/jvim.15977","volume":"35","author":"B Cuq","year":"2021","unstructured":"Cuq B, Blois SL, B\u00e9dard C, Wood RD, Abrams-Ogg AC, Beauchamp G, et al. Serum interleukin 17 concentrations in dogs with immune-mediated hemolytic anemia. J Vet Intern Med. 2021;35(1):217\u201325.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"277_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jvim.15441","volume":"33","author":"OA Garden","year":"2019","unstructured":"Garden OA, Kidd L, Mexas AM, Chang YM, Jeffery U, Blois SL, et al. ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. J Vet Intern Med. 2019;33(2):313\u201334.","journal-title":"J Vet Intern Med"},{"issue":"10","key":"277_CR21","first-page":"1100","volume":"58","author":"R Robbins","year":"2017","unstructured":"Robbins R, Viviano KR. Hypocholesterolemia and nonregenerative, suspected immune-mediated, anemia: report of 3 canine cases. Can Vet J. 2017;58(10):1100\u20134.","journal-title":"Can Vet J"},{"issue":"11","key":"277_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2460\/javma.2005.226.1869","volume":"226","author":"TK Weinkle","year":"2005","unstructured":"Weinkle TK, Center SA, Randolph JF, Warner KL, Barr SC, Erb HN. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993\u20132002). J Am Vet Med Assoc. 2005;226(11):1869\u201380.","journal-title":"J Am Vet Med Assoc"},{"issue":"6","key":"277_CR23","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cvsm.2003.08.003","volume":"33","author":"S McCullough","year":"2003","unstructured":"McCullough S. Immune-mediated hemolytic anemia: understanding the nemesis. Vet Clin North Am Small Anim Pract. 2003;33(6):1295\u2013315.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"8","key":"277_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2460\/javma.2001.218.1308","volume":"218","author":"PM McManus","year":"2001","unstructured":"McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994\u20131999). J Am Vet Med Assoc. 2001;218(8):1308\u201313.","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"277_CR25","first-page":"206","volume":"17","author":"N Mason","year":"2003","unstructured":"Mason N, Duval D, Shofer FS, Giger U. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med. 2003;17(2):206\u201312.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"277_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2460\/javma.2004.224.232","volume":"224","author":"SA Miller","year":"2004","unstructured":"Miller SA, Hohenhaus AE, Hale AS. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc. 2004;224(2):232\u20135.","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"277_CR27","first-page":"456","volume":"14","author":"K Burgess","year":"2000","unstructured":"Burgess K, Moore A, Rand W, Cotter SM. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med. 2000;14(4):456\u201362.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"277_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/jvim.15986","volume":"35","author":"VL Woolhead","year":"2021","unstructured":"Woolhead VL, Szladovits B, Chan A, Swann JW, Glanemann B. Breed predispositions, clinical findings, and prognostic factors for death in dogs with nonregenerative immune-mediated anemia. J Vet Intern Med. 2021;35(1):252\u201360.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"277_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1939-1676.2010.0656.x","volume":"25","author":"AM Mellett","year":"2011","unstructured":"Mellett AM, Nakamura RK, Bianco D. A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med. 2011;25(1):71\u20135.","journal-title":"J Vet Intern Med"},{"issue":"12","key":"277_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/avj.13016","volume":"98","author":"GM Woodward","year":"2020","unstructured":"Woodward GM, White JD. The utility of screening diagnostic tests in identifying associative immune-mediated haemolytic anaemia in dogs. Aust Vet J. 2020;98(12):586\u201390.","journal-title":"Aust Vet J"},{"issue":"3","key":"277_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cvsm.2022.01.009","volume":"52","author":"KR Viviano","year":"2022","unstructured":"Viviano KR, Glucocorticoids. Cyclosporine, azathioprine, Chlorambucil, and Mycophenolate in Dogs and cats: clinical uses, Pharmacology, and Side effects. Vet Clin North Am Small Anim Pract. 2022;52(3):797\u2013817.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"277_CR32","first-page":"101","volume":"7","author":"JW Swann","year":"2016","unstructured":"Swann JW, Skelly BJ. Canine autoimmune hemolytic anemia: management challenges. Vet Med (Auckl). 2016;7:101\u201312.","journal-title":"Vet Med (Auckl)"},{"issue":"4","key":"277_CR33","first-page":"230","volume":"29","author":"A Balch","year":"2007","unstructured":"Balch A, Mackin A. Canine immune-mediated hemolytic anemia: treatment and prognosis. Compend Contin Educ Vet. 2007;29(4):230\u20138. quiz 9.","journal-title":"Compend Contin Educ Vet"},{"key":"277_CR34","doi-asserted-by":"crossref","unstructured":"Weng J, Levy NA, Abbott HY, Mix JA, Wills RW, Mackin AJ et al. Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs. J Vet Intern Med. 2023.","DOI":"10.1111\/jvim.16652"}],"container-title":["Irish Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-024-00277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13620-024-00277-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-024-00277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T09:11:56Z","timestamp":1721898716000},"score":1,"resource":{"primary":{"URL":"https:\/\/irishvetjournal.biomedcentral.com\/articles\/10.1186\/s13620-024-00277-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1186\/s13620-024-00277-w","relation":{},"ISSN":["2046-0481"],"issn-type":[{"value":"2046-0481","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The materials and methods were reviewed and approved by the UCD Research Ethic Committee (AREC-E-21-02). Informed consent was obtained from the owners of all enrolled dogs prior to performing the diagnostic and treatment procedure including retrospective analysis of the medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All owners gave informed consent regarding the use of the data from their dog for publication (as stated in the standard informed consent signed by all owners upon presentation of their pet to the veterinary hospital).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}